Skip to main content

Advertisement

SpringerLink
Log in

Multidisciplinary treatment with chemotherapy, targeted drug, and high-intensity focused ultrasound in advanced pancreatic carcinoma

  • Case Report
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

This study reports a case of an advanced pancreatic cancer patient with liver metastasis who was treated with a combination of chemotherapy, targeted drugs, and high-intensity focused ultrasound (HIFU). The abdominal pain was successfully relieved after the HIFU therapy. The patient had an 18-month survival with satisfactory quality of life. Large-scale randomized clinical trials are necessary to evaluate the long-term efficacy of HIFU treatment with or without chemotherapy and/or targeted drug therapy for pancreatic carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Abbreviations

HIFU:

High-intensity focused ultrasound

NSCLC:

Non-small-cell lung cancer

GIST:

Gastrointestinal stromal tumor

References

  1. Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, et al. Talamonti MS. Validation of the 6th edition AJCC pancreatic cancer staging system: report from the national cancer database. Cancer. 2007;110:738–44.

    Article  PubMed  Google Scholar 

  2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.

    PubMed  CAS  Google Scholar 

  3. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21:2237–46.

    Article  PubMed  CAS  Google Scholar 

  4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.

    Article  PubMed  CAS  Google Scholar 

  5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.

    Article  PubMed  CAS  Google Scholar 

  6. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–45.

    Article  PubMed  CAS  Google Scholar 

  7. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol. 2004;11:465–75.

    Article  PubMed  Google Scholar 

  8. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6.

    Article  PubMed  CAS  Google Scholar 

  9. Wang X, Sun J. High-intensity focused ultrasound in patients with late-stage pancreatic carcinoma. Chin Med J. 2002;115:1332–5.

    PubMed  Google Scholar 

  10. Zhao H, Yang G, Wang D, Yu X, Zhang Y, Zhu J, Ji Y, Zhong B, Zhao W, Yang Z, Aziz F. Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer. Anticancer Drugs. 2010;21:447–52.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This study is supported by Zhejiang Provincial Natural Science Foundation of China, No. R2090353.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, 2nd Hospital of Zhejiang University College of Medicine, Hangzhou, Zhejiang, 310009, People’s Republic of China

    Ying Yuan, Hong Shen, Xiao-Ye Hu, Fei-Ying Gu, Mo-Dan Li & Xian Zhong

Authors
  1. Ying Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiao-Ye Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fei-Ying Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mo-Dan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xian Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hong Shen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yuan, Y., Shen, H., Hu, XY. et al. Multidisciplinary treatment with chemotherapy, targeted drug, and high-intensity focused ultrasound in advanced pancreatic carcinoma. Med Oncol 29, 957–961 (2012). https://doi.org/10.1007/s12032-011-9892-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-9892-1

Keywords

Search

Navigation